GILEAD SCIENCES INC

20 February, 2025

Gilead Sciences Reports Strong Sales Growth and Expands HIV Treatment Options with Promising New Drug Application for Lenacapavir

Gilead Sciences has shown impressive financial performance and growth potential, particularly through its leading HIV treatment, Biktarvy, which generated $13.4 billion in sales in 2024—a 13% year-on-...
Read More

19 February, 2025

Gilead Sciences Reports Strong Revenue Growth and Prepares for Competitive Launch in HIV Prevention Market Amid Broader Market Challenges

Gilead Sciences (GILD) continues to show strong performance in the biotechnology sector, with its HIV treatment Biktarvy generating $13.4 billion in sales for 2024, marking a 13% increase from the pre...
Read More

18 February, 2025

Gilead Anticipates Strong Growth with Upcoming Launch of Lenacapavir and Record Sales from Biktarvy as Stock Performance Remains Steady Amid Market Challenges

Gilead Sciences, Inc. (GILD) is poised for a significant year ahead as it prepares to launch lenacapavir as a pre-exposure prophylactic for HIV, anticipating FDA approval by mid-2025. During a recent ...
Read More

17 February, 2025

Gilead Sciences Achieves High Valuation Rating Amid Strong Revenue Growth and Upcoming HIV Prevention Launch

Gilead Sciences Inc. (GILD) currently holds a strong position in the Biotechnology & Drugs industry, evident from its high rating of 90% using Validea's Earnings Yield Investor model. This exceptional...
Read More